Clinical characteristics and outcomes of chédiak-Higashi syndrome: A nationwide survey of Japan

2013 ◽  
Vol 60 (10) ◽  
pp. 1582-1586 ◽  
Author(s):  
Kozo Nagai ◽  
Fumihiro Ochi ◽  
Kiminori Terui ◽  
Miho Maeda ◽  
Shouichi Ohga ◽  
...  
2019 ◽  
Vol 3 (4) ◽  
pp. 319-326 ◽  
Author(s):  
Hideaki Nakajima ◽  
Kenzo Uchida ◽  
Masakazu Takayasu ◽  
Takahiro Ushida

2018 ◽  
Vol 22 (5) ◽  
pp. 550-558 ◽  
Author(s):  
Aiko Terada ◽  
Masaki Komiyama ◽  
Tomoya Ishiguro ◽  
Yasunari Niimi ◽  
Hidenori Oishi

OBJECTIVEThis nationwide study was organized to evaluate the clinical characteristics, especially the annual detected rate, of pediatric intracranial arteriovenous (AV) shunts such as brain AV malformations (BAVMs), pial AV fistulas (PAVFs), vein of Galen aneurysmal malformations (VGAMs), and dural AV fistulas (DAVFs) in Japan.METHODSParticipation invitation emails for the study were sent to all members of the Japanese Society for Neuroendovascular Therapy and the Japanese Society for Pediatric Neurosurgery, totaling 4123 physicians. Excel files were attached to the emails to collect clinical data on patients aged 5 years old or younger with intracranial AV shunts at each hospital in the 5-year period from 2012 to 2016.RESULTSRepresentative physicians from 209 hospitals returned Excel files containing the patient data. Thirty-four hospitals reported on 72 patients with intracranial AV shunts. Among this cohort, 24 patients (33%) had BAVMs, 22 (31%) had PAVFs, 16 (22%) had VGAMs, and 10 (14%) had DAVFs. Male predominance (70%) was observed among all types of AV shunts. Most PAVFs (73%), VGAMs (88%), and DAVFs (100%) were diagnosed in patients younger than 1 year, especially neonates, whereas most BAVMs (92%) were diagnosed in children older than 1 year. In the patients older than 1 year, BAVMs were relatively common, and VGAMs and DAVFs were rare.CONCLUSIONSThe annual detected rates of BAVMs, PAVFs, VGAMs, and DAVFs in patients 5 years old or younger were 0.0775, 0.0710, 0.0517, and 0.0323 per 100,000 persons, respectively. In neonates and infants, VGAM, DAVF, and PAVF were relatively common, but BAVMs were extremely rare.


2020 ◽  
Vol 67 (8) ◽  
pp. 853-857
Author(s):  
Shuichi Yatsuga ◽  
Naoko Amano ◽  
Akari Nakamura-Utsunomiya ◽  
Hironori Kobayashi ◽  
Kei Takasawa ◽  
...  

Medicine ◽  
2017 ◽  
Vol 96 (29) ◽  
pp. e7387 ◽  
Author(s):  
Jin-Ho Choi ◽  
Beom Hee Lee ◽  
Sun Hee Heo ◽  
Gu-Hwan Kim ◽  
Yoo-Mi Kim ◽  
...  

2021 ◽  
Vol 11 ◽  
pp. 204512532110202
Author(s):  
Dragana Ignjatovic Ristic ◽  
Dan Cohen ◽  
Ivan Ristic

Objective: Despite clozapine being the most effective treatment for treatment-resistant schizophrenia (TRS), a clear explanation as to why it is underutilized and why its initiation is delayed remains unclear. The first aim of the study was to conduct a nation-wide assessment of both the psychiatrists’ attitudes of the obstacles for prescribing clozapine as well as their prescription practices. The second aim was to make recommendations, based on the results obtained, for improving the Serbian clozapine guidelines. Methods: A questionnaire was conducted consisting of two parts. One regarded the clinical characteristics of the psychiatrists, while the second contained questions about indications for clozapine initiation, clozapine prescribing tendencies, and barriers to clozapine use. The questionnaire was sent to 302 Serbian psychiatrists. Results: With 161 out of the 302 psychiatrists returning the questionnaires, the response rate was 53.3%. Nearly 60% of the psychiatrists treated 10 or more patients with clozapine, with TRS being the most common indication. Only four psychiatrists (2.5%) had no patients currently on clozapine. Psychiatrists indicated that their fear of agranulocytosis (68%) constituted the greatest obstacle for clozapine prescription, followed closely by weight gain (56%), and sedation (39%). Despite their fear of agranulocytosis, only 83.9% of the psychiatrists monitored leukocytes regularly. Conclusion: In general, psychiatrists in Serbia seem to be confident in prescribing clozapine, even in the absence of clear monitoring guidelines and the possibility of therapeutic drug monitoring. In order to reduce obstacles for clozapine prescription, monitoring laxity, and an overreliance on personal experience, we recommend three modifications of the existing clozapine guideline.


Sign in / Sign up

Export Citation Format

Share Document